Skip to main content
BRAIN Biotech AG logo

BRAIN Biotech AG — Investor Relations & Filings

Ticker · BNN ISIN · DE0005203947 LEI · 391200JKPVHLD6JLZ107 F Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2024-08-29 Interim / Quarterly Rep…
Country DE Germany
Listing F BNN

About BRAIN Biotech AG

https://www.brain-biotech.com/

BRAIN Biotech AG is an industrial biotechnology company specializing in the discovery, development, and production of specialty enzymes, high-performance microorganisms, and bioactive compounds. The company provides tailor-made biosolutions and contract research and development (R&D) services to partners in the food, chemical, and life sciences sectors. Core competencies include enzyme technology, microbial strain development, and bioprocess development. By leveraging an advanced technology portfolio, which includes proprietary platforms for enzyme discovery and genome editing, the company enables its partners to create more sustainable and efficient industrial products and processes, contributing to the bioeconomy.

Recent filings

Filing Released Lang Actions
Q3 statement / Q3 financial report 2023/2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for BRAIN Biotech AG covering the period from 1 April 2024 to 30 June 2024. It contains comprehensive financial data, including a consolidated income statement, balance sheet, cash flow statement, and notes to the financial statements. Since it covers a period shorter than a full fiscal year and provides substantive financial data rather than just an announcement or certification, it is classified as an Interim/Quarterly Report. Q2 2024
2024-08-29 English
BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
Board/Management Information Classification · 100% confidence The document is a news release dated May 29, 2024, announcing the appointment of Erik de Vries as Senior Business Development Director Enzymes at BRAIN Biotech AG. This type of announcement concerns changes in senior personnel. Reviewing the definitions, the 'Board/Management Information (Code: MANG)' category specifically covers 'Announcement of changes in the company's board of directors or senior management.' The content directly aligns with this definition. It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2024-05-29 English
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets
Earnings Release Classification · 100% confidence The document explicitly states it 'today published its half year results, 6M 2023/2024' and provides detailed financial figures for the first six months (6M) of the financial year, including revenues, EBITDA, and segment performance comparisons. The keyword 'Half Year Results/Half Year Report' is present. This directly corresponds to the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K) because it covers only six months, nor is it just an Earnings Release (ER) as it contains detailed segment breakdowns and financial tables typical of a comprehensive interim report. H1 2024
2024-05-28 English
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.10.2023 bis zum 31.03.2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halbjahresfinanzbericht' (Half-Year Financial Report) for BRAIN Biotech AG covering the period from October 1, 2023, to March 31, 2024. It contains comprehensive financial statements, including the consolidated income statement, management discussion and analysis (Konzernzwischenlagebericht), and segment reporting. As it provides substantive financial data for an interim period (6 months), it is classified as an Interim/Quarterly Report. H1 2024
2024-05-28 German
Half-yearly financial report 2023/2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'HALF-YEAR REPORT' for BRAIN Biotech AG covering the period ending 31 March 2024. It contains comprehensive financial statements, including the consolidated income statement, balance sheet, cash flow statement, and interim management report. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-05-28 English
Report Publication Announcement 2024
Report Publication Announcement Classification · 100% confidence The document is titled "Preliminary announcement of the publication of financial reports" and explicitly states that the company is announcing *when* and *where* specific financial reports (specifically, the 'Financial report of the group (half-year/Q2)') will be disclosed on a future date (May 28, 2024). The document itself is very short (under 2,000 characters) and serves only to announce the upcoming release of the actual report, not to contain the report's content. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report will be published points directly to the 'Report Publication Announcement' category.
2024-05-14 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.